231 related articles for article (PubMed ID: 19057212)
21. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
22. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
da Silva CM; Cruz F
Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
[TBL] [Abstract][Full Text] [Related]
23. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?
Gravas S; Melekos MD
Curr Opin Urol; 2009 Jan; 19(1):49-54. PubMed ID: 19057216
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin injection therapy in the management of lower urinary tract dysfunction.
Patel AK; Chapple CR
Int J Clin Pract Suppl; 2006 Dec; (151):1-7. PubMed ID: 17169004
[TBL] [Abstract][Full Text] [Related]
25. Effects of botulinum toxin A on the contractile function of dog prostate.
Lin AT; Yang AH; Chen KK
Eur Urol; 2007 Aug; 52(2):582-9. PubMed ID: 17386969
[TBL] [Abstract][Full Text] [Related]
26. Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation.
Minamoto VB; Hulst JB; Lim M; Peace WJ; Bremner SN; Ward SR; Lieber RL
Dev Med Child Neurol; 2007 Dec; 49(12):907-14. PubMed ID: 18039237
[TBL] [Abstract][Full Text] [Related]
27. Botox and the prostate: a new wrinkle.
Harv Mens Health Watch; 2005 Oct; 10(3):7-8. PubMed ID: 16296161
[No Abstract] [Full Text] [Related]
28. Treatment options for benign prostatic hyperplasia in older men.
Miano R; De Nunzio C; Asimakopoulos AD; Germani S; Tubaro A
Med Sci Monit; 2008 Jul; 14(7):RA94-102. PubMed ID: 18591930
[TBL] [Abstract][Full Text] [Related]
29. Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment.
Sein Anand J; Chodorowski Z; Hajduk A
Przegl Lek; 2005; 62(6):522-3. PubMed ID: 16225113
[TBL] [Abstract][Full Text] [Related]
30. Investigating botulinum toxin A on the functional properties of the prostate.
Choo MS
Eur Urol; 2007 Aug; 52(2):324-5. PubMed ID: 17376584
[No Abstract] [Full Text] [Related]
31. Animal models for benign prostatic hyperplasia.
Hieble JP
Handb Exp Pharmacol; 2011; (202):69-79. PubMed ID: 21290222
[TBL] [Abstract][Full Text] [Related]
32. [The role of alpha1-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench].
Kojima Y; Hayase M; Imura M; Okada S; Kubota Y; Sasaki S; Hayashi Y; Kohri K
Hinyokika Kiyo; 2008 Jun; 54(6):457-62. PubMed ID: 18634446
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.
Karsenty G; Rocha J; Chevalier S; Scarlata E; Andrieu C; Zouanat FZ; Rocchi P; Giusiano S; Elzayat EA; Corcos J
Prostate; 2009 Aug; 69(11):1143-50. PubMed ID: 19399787
[TBL] [Abstract][Full Text] [Related]
34. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia.
Kang KK; Kim JM; Yu JY; Ahn BO; Yoo M; Kim YC
Int J Urol; 2007 Oct; 14(10):946-51; discussion 951. PubMed ID: 17880297
[TBL] [Abstract][Full Text] [Related]
35. What's truly minimally invasive in benign prostatic hyperplasia surgery?
Chung A; Woo HH
Curr Opin Urol; 2014 Jan; 24(1):36-41. PubMed ID: 24247171
[TBL] [Abstract][Full Text] [Related]
36. Is botulinum toxin type a intraprostatic injections really effective in patients with urinary retention?
Jasiński M; Drewa T; Tyloch J; Wolski Z
Acta Pol Pharm; 2011; 68(5):765-8. PubMed ID: 21928723
[TBL] [Abstract][Full Text] [Related]
37. Intra-prostatic injection of botulinum toxin type A in treatment of dogs with spontaneous benign prostatic hyperplasia.
Mostachio GQ; Apparício M; Motheo TF; Alves AE; Vicente WR
Anim Reprod Sci; 2012 Aug; 133(3-4):224-8. PubMed ID: 22819377
[TBL] [Abstract][Full Text] [Related]
38. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
39. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm.
Barkin J
Can J Urol; 2008 Aug; 15 Suppl 1():21-30; discussion 30. PubMed ID: 18700062
[TBL] [Abstract][Full Text] [Related]
40. Re: Athanassios Oeconomou, Helmut Madersbacher, Gustav Kiss, Thomas J. Berger, Michael Melekos and Peter Rehder. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? a review of the literature. Eur Urol 2008;54:765-77.
Brisinda G; Vanella S; Maria G
Eur Urol; 2009 Jul; 56(1):e10-1; author reply e12-3. PubMed ID: 19375845
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
